Ipratropio Bromuro Cipla

Ipratropium bromide, the active ingredient in Ipratropio Bromuro Cipla, is an anticholinergic presented as an inhalation solution for inhalation use. It produces bronchodilation by blocking muscarinic receptors, helping to control symptoms of chronic obstructive pulmonary disease (COPD) and asthma in adult patients.

GNH USA supplies Ipratropio Bromuro Cipla as a licensed, GMP‑certified, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics worldwide under strict quality and regulatory standards. The company’s global logistics network ensures timely delivery and compliance with import regulations across multiple regions.

Ipratropium bromide is an anticholinergic bronchodilator used in the management of obstructive airway diseases.

- Chronic obstructive pulmonary disease (COPD): improves airflow and reduces the frequency of exacerbations. - Asthma: provides additional bronchodilation as add‑on therapy to improve symptom control. - Chronic bronchitis: helps relieve bronchospasm and enhances breathing comfort.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth: sensation of reduced salivation. - Cough: irritation of the throat during inhalation. - Throat irritation: mild soreness or discomfort. - Headache: transient mild headache. - Dizziness: occasional light‑headed feeling. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Urinary retention: difficulty emptying the bladder. - Exacerbation of narrow‑angle glaucoma: increased intra‑ocular pressure. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Tachycardia: rapid heart rate in susceptible individuals.

Before prescribing ipratropium bromide, clinicians should consider several safety aspects.

- Assess renal function: adjust use in severe renal impairment. - Monitor for anticholinergic effects: watch for dry mouth, constipation, or blurred vision. - Avoid use in patients with narrow‑angle glaucoma: may worsen intra‑ocular pressure. - Use with caution in patients with urinary retention: may exacerbate symptoms. - Store at room temperature: keep in the original container, protect from moisture and light.

Ipratropium bromide can interact with other medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent use with other anticholinergic agents: may increase anticholinergic burden. - Combination with beta‑agonists: may cause additive bronchodilation and potential tachycardia. - Use with MAO inhibitors: limited data, avoid unless necessary.

Moderate Interactions (Monitor Closely): - Inhaled corticosteroids: monitor for local irritation. - Diuretics: may increase risk of dry mouth. - Ophthalmic anticholinergics: monitor intra‑ocular pressure in glaucoma patients.